Garanzini Michael 4
4 · EYEGATE PHARMACEUTICALS INC · Filed Apr 18, 2018
Insider Transaction Report
Form 4
Garanzini Michael
Chief Commercial Officer
Transactions
- Purchase
Common Stock
2018-04-17+156,250→ 171,250 total - Purchase
Warrants (right to buy)
2018-04-17+156,250→ 156,250 totalExercise: $0.32From: 2018-04-17Exp: 2023-04-17→ Common Stock (156,250 underlying)
Footnotes (1)
- [F1]The reported securities were purchased by the reporting person for a combined purchase price of $0.32 per share of common stock and warrant in connection with the Issuer's public offering that closed on April 17, 2018. Each warrant will be exercisable during the period commencing on April 17, 2018 and ending on April 17, 2023 at an exercise price of $0.32.